22 Enrolled - GlaxoSmithKline TIMI 52

This was one of our first trials to work with Houston Metropolitan Cardiology. The design of the trial was to test the study drug for reduction in future major cardiovascular events after patients experienced a recent major cardiovascular event. We had 22 patients enrolled between 3 sites, which we consolidated to 2 sites after the first year. Most patients participated for over 3 years in this endpoint-driven trial. 

 A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)